Dr. Marina Vaysburd, MD

Dr. Vaysburd practices at Cedars-Sinai Endoscopy in Beverly Hills, California.

Dr. Vaysburd's NPI, 1689784712, was assigned on August 30, 2006. Dr. Vaysburd graduated from Stanford University School Of Medicine in 1996. Dr. Vaysburd holds California license A64864.

Dr. Vaysburd's primary practice is Cedars-Sinai Endoscopy, at 200 N Robertson Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 385-3239.

Dr. Vaysburd's primary practice is Cedars-Sinai Endoscopy in Beverly Hills, California. Dr. Vaysburd is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Vaysburd to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vaysburd practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Vaysburd's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Vaysburd is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Vaysburd's licenses on file in 2 states: California and Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Vaysburd treats.

CMS data shows 839 Medicare services from Dr. Vaysburd across 6 procedure codes in 2024, for 268 Medicare patients. Medicare paid $79,066 for them. Every service was in an office.

CMS counts 268 Medicare patients who saw Dr. Vaysburd in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vaysburd's median patient age at 70, with 86% women.

In 2024, Dr. Vaysburd wrote 892 Medicare Part D claims for 177 patients. 92% of them were for generic drugs. CMS names the drug for 835 of them, across 11 drugs with 11 or more claims each, at $685,067 in total drug cost. In 2023, CMS named 865 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Vaysburd for performance year 2024, reported as part of a group. Dr. Vaysburd accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vaysburd as offering telehealth.

Dmand AI links 25 papers to Dr. Vaysburd, published from 2013 to 2024. 2023 was the busiest year, with 5. The most frequent topics are Ribonucleoproteins, tau Proteins and Antibodies, Viral. Dr. Vaysburd has published most often in EMBO J.

CMS Open Payments shows 1,040 general payments to Dr. Vaysburd from 57 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. AstraZeneca Pharmaceuticals LP paid the most, $78,258.

Dmand AI lists 1 award for Dr. Vaysburd, most recently CMS Stage 1 EHR in 2013.

Dr. Vaysburd graduated from Stanford University School Of Medicine in 1996. Dr. Vaysburd is a member of ASCO.

Dr. Vaysburd is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.